A lipid-lowering and anti-obesity ginger notoginseng extract and its application
Through the preparation method of ginger Panax notoginseng extract, the problem of major side effects of existing anti-obesity drugs was solved, and lipid-lowering and anti-obesity ginger Panax notoginseng extract was obtained, which significantly reduced the triglyceride content and body weight of mice. It improves obesity-related metabolic syndrome and has good application prospects.
Patent Information
- Application Number
- CN202410631289.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-21
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-05-21
AI Technical Summary
Existing anti-obesity drugs have obvious side effects and lack safe and effective lipid-lowering and anti-obesity treatment options. Especially in the treatment of obesity and metabolic diseases, traditional Chinese medicine has advantages, but the lipid-lowering and anti-obesity activities of ginger Panax notoginseng Not fully studied.
The preparation method of ginger Panax notoginseng extract includes pulverization, ethanol leaching, ethyl acetate extraction and gradient elution. The D101 macroporous resin column is elution in segments using ethanol-water mixed solvents of different concentrations to obtain lipid-lowering Anti-obesity ginger Panax notoginseng extract.
The prepared Panax notoginseng extract significantly reduces the triglyceride content in pre-adipocytes of mice, inhibits weight gain, reduces fat accumulation in adipose tissue and liver, improves obesity-related metabolic syndrome, and reduces blood triglycerides and blood cholesterol concentrations. , relieves insulin resistance and has no toxic side effects.
Smart Images

Figure CN118477155B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of anti-obesity drugs, and particularly relates to a lipid-lowering and anti-obesity ginger notoginseng extract and application thereof. Background Art
[0002] Obesity is a chronic metabolic disease characterized by excessive accumulation of body fat and abnormal body weight. It often induces and increases the risk of many chronic diseases, such as hypertension, type II diabetes, and cardiovascular and cerebrovascular diseases, which seriously reduces human life expectancy and quality of life. The pathogenesis of obesity is affected by many factors such as genetics, metabolism, behavior, and environment, which is complicated, thus posing a huge challenge to the development of anti-obesity treatment methods and drugs. At present, the treatment methods for obesity are lifestyle intervention, surgical treatment, and drug therapy. However, the first two methods have poor compliance and high risks, so the research and development of anti-obesity drugs has good application prospects.
[0003] Orlistat is currently the only anti-obesity drug approved for marketing in China, but its side effects are obvious, including diarrhea, fecal incontinence, oily spots, gastrointestinal flatulence and indigestion, so there is an urgent need to develop safe and effective anti-obesity drugs. Compared with Western medicine, traditional Chinese medicine has unique advantages in the treatment of metabolic diseases such as obesity, such as low toxicity and side effects, and low resistance to drugs. In recent years, it has been favored by anti-obesity drug researchers.
[0004] Ginger Panax notoginseng, also known as Radix Notoginseng or Radix Notoginseng, belongs to the genus Radix Notoginseng of the Zingiberaceae family and is a folk herbal medicine of the Dai people included in the "Chinese Dai Medicine Records". So far, there has been no research and report on the lipid-lowering and anti-obesity activities of Ginger Panax notoginseng. Summary of the invention
[0005] The technical problem to be solved by the present invention is to provide a lipid-lowering and anti-obesity ginger Panax notoginseng extract and its application. The process is simple and easy. The prepared lipid-lowering and anti-obesity ginger Panax notoginseng extract has good lipid-lowering and anti-obesity effects, has no toxic side effects, and has good application prospects in the directions of anti-obesity, lowering blood lipids and lowering blood sugar.
[0006] In order to solve the above technical problems, the present invention provides a lipid-lowering and anti-obesity ginger notoginseng extract, and the preparation method thereof comprises the following steps:
[0007] (1) crushing the raw materials: drying the ginger notoginseng and crushing it;
[0008] (2) ethanol extraction: adding ethanol to the raw material for extraction and concentrating under reduced pressure to obtain ethanol extract of Panax notoginseng;
[0009] (3) Ethyl acetate extraction: The ethanol extract of Panax notoginseng is suspended and dissolved in distilled water, and ethyl acetate is added for extraction, and the solvent is concentrated under reduced pressure to recover the solvent, thereby obtaining the ethyl acetate extract of Panax notoginseng;
[0010] (4) Gradient elution: Using a macroporous resin column, an ethanol-water mixed solvent is used to elute the ethyl acetate extract of Panax notoginseng, the eluate is collected, and the solvent is removed by vacuum concentration to obtain the lipid-lowering and anti-obesity Panax notoginseng extract.
[0011] Furthermore, the specific method for eluting in step (4) is: using a D101 macroporous resin column, sequentially using three different concentrations of ethanol-water mixed solvents to segmentally elute the notoginseng ethyl acetate extract, wherein the concentration of the ethanol-water mixed solvent in the first segment is greater than or equal to 0:1 and less than or equal to 1:1; the concentration of the ethanol-water mixed solvent in the second segment is greater than 1:1 and less than or equal to 4:1; the concentration of the ethanol-water mixed solvent in the third segment is greater than 4:1 and less than or equal to 19:1; respectively collecting the corresponding eluents, and performing reduced pressure concentration to remove the solvent, and sequentially obtaining three elution components: a first segment ethanol macroporous phase, a second segment ethanol macroporous phase and a third segment ethanol macroporous phase; the lipid-lowering and anti-obesity notoginseng extract includes at least one of the first segment ethanol macroporous phase, the second segment ethanol macroporous phase and the third segment ethanol macroporous phase.
[0012] Furthermore, the specific method for eluting in step (4) is: using a D101 macroporous resin column, sequentially using three different concentrations of ethanol-water mixed solvents to segmentally elute the notoginseng ethyl acetate extract, wherein the concentration of the ethanol-water mixed solvent in the first segment is 1:1; the concentration of the ethanol-water mixed solvent in the second segment is equal to 4:1; the concentration of the ethanol-water mixed solvent in the third segment is equal to 19:1; the corresponding eluates are collected respectively, and concentrated under reduced pressure to remove the solvent, and three elution components are obtained in sequence: the first segment ethanol macroporous phase, the second segment ethanol macroporous phase and the third segment ethanol macroporous phase; the lipid-lowering and anti-obesity notoginseng extract is the second segment ethanol macroporous phase.
[0013] Furthermore, the specific method of ethanol extraction in step (2) is: adding 95% ethanol to the raw material for extraction at room temperature for 3 times, the amount of ethanol added each time is 3-5 times the volume of the raw material, the extraction time is 7 days each time, the 3 extracts are combined and concentrated under reduced pressure to obtain the ginger notoginseng ethanol extract.
[0014] Furthermore, the specific method of ethyl acetate extraction in step (3) is to suspend and dissolve the ethanol extract of Panax notoginseng with 5 times the volume of distilled water, add an equal volume of ethyl acetate solvent to extract 3 times, combine the ethyl acetate extracts and concentrate under reduced pressure to recover the solvent, so as to obtain the ethyl acetate extract of Panax notoginseng.
[0015] Furthermore, the Panax notoginseng includes at least one of its leaves, stems, and roots.
[0016] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the lipid-lowering and anti-obesity ginger notoginseng extract.
[0017] The present invention also provides the use of the lipid-lowering and anti-obesity ginger notoginseng extract or the pharmaceutical composition in the preparation of products for preventing and / or treating obesity and reducing lipids.
[0018] The present invention also provides the use of the lipid-lowering and anti-obesity ginger notoginseng extract or the pharmaceutical composition in the preparation of products for preventing and / or treating diabetes and lowering blood sugar.
[0019] Beneficial effects of the present invention:
[0020] The lipid-lowering anti-obesity ginger Panax notoginseng extract of the present invention can significantly reduce the triglyceride content in mouse preadipocytes 3T3-L1, and the cytotoxicity is relatively low; it significantly inhibits weight gain in obese mice induced by a high-fat diet (HFD), can reduce liver fat accumulation in a dose-dependent manner, and reduce the volume of fat cells in adipose tissue; it can significantly alleviate obesity-related metabolic syndrome in obese mice induced by a high-fat diet, including reducing the blood triglyceride and blood cholesterol concentrations of obese mice, and improving glucose tolerance damage caused by a high-fat diet; it can alleviate the insulin resistance in obese mice, improve insulin sensitivity, and reduce symptoms such as fatty liver and liver degeneration, and has no obvious toxicity to the liver and kidneys. The process of the present invention is simple and easy, and the prepared lipid-lowering anti-obesity ginger Panax notoginseng extract has good lipid-lowering and anti-obesity effects, no toxic side effects, and has good application prospects in the directions of anti-obesity, lowering blood lipids and lowering blood sugar. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 Oil Red O staining of the triglyceride content in mouse preadipocytes 3T3-L1;
[0022] Figure 2 The results of the determination of triglyceride content in mouse preadipocytes 3T3-L1;
[0023] Figure 3 This is the curve of body weight change over time in obese mice induced by high-fat diet (HFD);
[0024] Figure 4 The statistical results of daily food intake of experimental mice;
[0025] Figure 5 Oil red O and H&E staining of liver, abdominal adipose tissue, and kidney tissue sections of HFD-induced obese mice;
[0026] Figure 6 The results of the determination of triglyceride content in serum of HFD-induced obese mice;
[0027] Figure 7 The results of the determination of serum cholesterol content in HFD-induced obese mice;
[0028] Figure 8 This is the change curve of glucose tolerance (OGTT) in HFD-induced obese mice;
[0029] Fig. 9 This is the change curve of insulin sensitivity (ITT) in HFD-induced obese mice. DETAILED DESCRIPTION
[0030] The specific embodiments of the present invention are further described below in conjunction with the accompanying drawings. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0031] Example 1
[0032] A lipid-lowering and anti-obesity ginger notoginseng extract, the preparation method of which comprises the following steps:
[0033] (1) crushing the raw materials: drying the ginger notoginseng and then crushing it; the ginger notoginseng includes at least one of its leaves, stems, and roots;
[0034] (2) Ethanol extraction: 95% ethanol was added to the raw material for extraction at room temperature for 3 times, and the amount of ethanol added each time was 3 times the volume of the raw material. The extraction time was 7 days each time, and the 3 extracts were combined and concentrated under reduced pressure to obtain the ginger notoginseng ethanol extract;
[0035] (3) Ethyl acetate extraction: The ethanol extract of Panax notoginseng was suspended and dissolved in 5 times the volume of distilled water, and an equal volume of ethyl acetate solvent was added for extraction 3 times. The ethyl acetate extracts were combined and concentrated under reduced pressure to recover the solvent, thereby obtaining the ethyl acetate extract of Panax notoginseng;
[0036] (4) Gradient elution: using a D101 macroporous resin column, three different concentrations of ethanol-water mixed solvents are used in sequence to elute the ethyl acetate extract of Panax notoginseng in sections, wherein the concentration of the ethanol-water mixed solvent in the first section is equal to 0:1; the concentration of the ethanol-water mixed solvent in the second section is equal to 1.5:1; and the concentration of the ethanol-water mixed solvent in the third section is equal to 4.5:1; the corresponding eluates are collected and concentrated under reduced pressure to remove the solvent, thereby obtaining three elution components in sequence: a first section of ethanol macroporous phase, a second section of ethanol macroporous phase and a third section of ethanol macroporous phase; wherein the preferred lipid-lowering and anti-obesity Panax notoginseng extract comprises at least the third section of ethanol macroporous phase.
[0037] Example 2
[0038] A lipid-lowering and anti-obesity ginger notoginseng extract, the preparation method of which comprises the following steps:
[0039] (1) crushing the raw materials: drying the ginger notoginseng and then crushing it; the ginger notoginseng includes at least one of its leaves, stems, and roots;
[0040] (2) Ethanol extraction: 95% ethanol was added to the raw material for extraction at room temperature for 3 times, and the amount of ethanol added each time was 5 times the volume of the raw material. The extraction time was 7 days each time, and the 3 extracts were combined and concentrated under reduced pressure to obtain the ginger notoginseng ethanol extract;
[0041] (3) Ethyl acetate extraction: The ethanol extract of Panax notoginseng was suspended and dissolved in 5 times the volume of distilled water, and an equal volume of ethyl acetate solvent was added for extraction three times. The ethyl acetate extracts were combined and concentrated under reduced pressure to recover the solvent to obtain the ethyl acetate extract of Panax notoginseng (JST-EtOAc);
[0042] (4) Gradient elution: Using a D101 macroporous resin column, three different concentrations of ethanol-water mixed solvents are used in sequence to elute the ethyl acetate extract of Panax notoginseng in sections, wherein the concentration of the ethanol-water mixed solvent in the first section is 1:1; the concentration of the ethanol-water mixed solvent in the second section is 4:1; and the concentration of the ethanol-water mixed solvent in the third section is 19:1. The eluents of corresponding proportions are collected respectively, and the solvent is removed by vacuum concentration to obtain three elution components in sequence: the first section ethanol macroporous phase (JST-50%), the second section ethanol macroporous phase (JST-80%) and the third section ethanol macroporous phase (JST-95%); the lipid-lowering and anti-obesity Panax notoginseng extract includes at least the second section ethanol macroporous phase (JST-80%).
[0043] Example 3
[0044] A pharmaceutical composition comprises a therapeutically effective amount of the lipid-lowering and anti-obesity ginger notoginseng extract.
[0045] Example 4
[0046] The lipid-lowering and anti-obesity ginger Panax notoginseng extract or the pharmaceutical composition is used in the preparation of products for preventing and / or treating obesity and lowering lipids.
[0047] Example 5
[0048] The lipid-lowering and anti-obesity ginger Panax notoginseng extract or the pharmaceutical composition is used in the preparation of products for preventing and / or treating diabetes and lowering blood sugar.
[0049] In order to verify the relevant physical and chemical properties of the lipid-lowering and anti-obesity ginger Panax notoginseng extract, the JST-EtOAc, JST-50%, JST-80%, and JST-95% prepared in Example 2 were used to conduct the following experiments:
[0050] Example 6
[0051] Cytotoxicity test of 3T3-L1 preadipocytes
[0052] When the density of 3T3-L1 preadipocytes reaches 80%-90%, the plates are plated. 5000 cells are inoculated in each well of a 96-well plate, and the culture system is 100μL. After culturing for 24h-36h, 8 groups of drug administration are set up after the cells adhere to the wall, namely, high concentration (12.5μg / mL) and low concentration (6.25μg / mL) of ethyl acetate extraction phase (JST-EtOAc), 50% ethanol macroporous phase (JST-50%), 80% ethanol macroporous phase (JST-80%), 95% ethanol macroporous phase (JST-95%) are given respectively. A blank control group is also set up (the wells containing cells with a drug dose of 0, and the cell viability of this group is regarded as 100% in the experiment). After 48h of drug administration, 0.5mg / mL MTT is given, incubated at 37℃ for 4h, and then an equal volume of DMSO is added to dissolve the formazan precipitate, and the OD is measured. 570 Absorbance value. Inhibition rate of the compound in the drug-added group = 1-OD value of the drug-added group / OD value of the control group. Finally, set up gradient concentration rescreening and use Graphpad software to calculate the half-inhibitory concentration IC 50 The value (drug concentration required when the number of surviving cells is reduced by half after drug administration) is shown in the following table:
[0053]
[0054] From IC 50 The test data showed that the cytotoxicity of the four ginger notoginseng extracts and fractions was relatively low, among which JST-80% had an IC value of 0.0447 for 3T3-L1 cells within 48 hours. 50 It is 24.80±2.59μg / mL.
[0055] Example 7
[0056] Lipid-lowering activity test of 3T3-L1 preadipocytes
[0057] (1) Culture medium and reagents used in the experiment:
[0058] Basic culture medium: DMEM high-glucose culture containing 10% fetal bovine serum and 1% penicillin-streptomycin.
[0059] Cell differentiation induction solution I: 500 μmol / L 3-isobutyl-1-methylxanthine (IBMX), 100 ng / mL dexamethasone, 2 μg / mL insulin, 1 μmol / L rosiglitazone, 10% fetal bovine serum, and 1% p / s DMEM culture medium.
[0060] Cell differentiation induction medium II: DMEM culture medium containing 2 μg / mL insulin, 10% fetal bovine serum and 1% p / s.
[0061] (2) Experimental group settings:
[0062] 3T3-L1 cells in the logarithmic growth phase were plated, 20,000 cells were inoculated in each well of a 48-well plate, and cultured with basal medium at 5% CO2 and 37°C; when the cells grew to 100% complete confluence, an undifferentiated control group (UND), a differentiated control group (Vehicle) and a drug-treated group (a total of 8 drug treatments) were set up and cultured for 9 days respectively.
[0063] Undifferentiated control group (UND): The cells were cultured with basal medium from day 1 to day 9, and the medium was changed every three days.
[0064] Differentiation control group (Vehicle): on days 1-3, use cell differentiation induction solution I; on days 4-6, use cell differentiation induction solution II; on days 7-9, use basal culture medium.
[0065] Drug treatment group: On days 1-3, cells were cultured with different concentrations (20, 10, 5, 2.5, 1.25, 0.63, 0.31, 0.15 μmol / L) of the compound (drug solution) prepared in cell differentiation induction solution I; on days 4-6, cells were cultured with different concentrations (20, 10, 5, 2.5, 1.25, 0.63, 0.31, 0.15 μmol / L) of the compound (drug solution) prepared in cell differentiation induction solution II; on days 7-9, cells were cultured with different concentrations (20, 10, 5, 2.5, 1.25, 0.63, 0.31, 0.15 μmol / L) of the compound (drug solution) prepared in basal culture medium.
[0066] The above-mentioned cultures were carried out twice, one group of cells was used for Oil Red O staining experiment, and the other group of cells was used to determine the content of triglyceride (TG).
[0067] (3) Oil Red O staining:
[0068] After the culture was completed, the upper layer of culture medium was discarded, and the cells were gently rinsed with 1×PBS, and fixed with 4% paraformaldehyde at room temperature for more than 30 minutes. The upper layer of liquid was then aspirated, and 0.3% Oil Red O staining solution was added to stain for 30 minutes in the dark. Afterwards, the cells were gently rinsed with tap water, and appropriate amount of deionized water was added. Microscopic photographs were taken to obtain the Oil Red O staining micrographs of each group, as shown in the figure. Figure 1 shown.
[0069] (4) Quantitative detection of triglycerides (TG):
[0070] After the cell culture is completed, discard the culture medium, gently rinse once with PBS, add 50μL of 2% Triton X-100 (diluted with ddH2O) to each well, and lyse for 40-60 minutes until the cells are completely lysed. Take a 96-well plate, add 200μL of TG working solution to each well, and then add 10μL of cell sample and 2μL of standard to each well. Set up a blank group, add 200μL of working solution and 10μL of 2% Triton X-100, and mix well. Incubate at 37℃ for 10-15 minutes, and measure OD 510 Absorbance value. The protein concentration of the cell sample was measured with a BCA protein quantification kit, and the TG content was calculated according to the following formula (the standard concentration was 2.26mmol / L). Where: TG content (mmol / gprot) = [(sample OD value - blank OD value) / (calibrator OD value - blank OD value)] × calibration concentration (mmol / L) ÷ protein concentration of the sample to be tested (gprot / L). The TG content of each group is as follows Figure 2 Finally, set up gradient concentration rescreening and use Graphpad software to calculate EC 50 Value (concentration that inhibits 50% of the maximum effect of triglycerides), the calculation results are shown in the following table:
[0071]
[0072] From EC 50 The test data showed that the four ginger notoginseng extracts and fractions could significantly reduce the triglyceride content in mouse preadipocytes 3T3-L1, among which JST-80% had the best lipid-lowering activity, EC 50 The value was 8.24±0.13μg / mL. In addition, from the selectivity index, IC 50 / EC 50 It can also be seen from the values that the JST-80% extract has a lower cytotoxic activity and is the most active fraction in the ethyl acetate extract phase.
[0073] Example 8
[0074] In vivo evaluation of anti-obesity activity
[0075] Fifty C57BL / 6 mice were randomly divided into 5 groups (10 mice in each group) after one week of adaptive feeding: normal diet group, obesity model group (HFD diet), positive drug control group (orlistat, HFD+Orlistat, administered at a dose of 40 mg / kg according to the body weight of mice) and 2 HFD+JST-80% fraction administration groups (high dose: administered at a dose of 120 mg / kg according to the body weight of mice; low dose: administered at a dose of 40 mg / kg according to the body weight of mice).
[0076] Each group of mice was given free water, the normal diet group was given maintenance feed, and the other groups were given 60% high-fat feed for 8 weeks (at this time, the average weight of mice in the high-fat diet group exceeded that of the normal diet group by more than 20%). After 8 weeks, the fraction administration group and the positive drug control group were gavaged (the gavage volume was calculated according to the dosage of each mouse by gavage of 0.2 ml of medicine per 10 g of mouse body weight, and the drug was prepared with 0.5% CMC-Na) and the Chinese medicine extract JST-80% (high dose: 120 mg / kg and low dose: 40 mg / kg) prepared in Example 2 and the positive drug Orlistat (Orlistat, 40 mg / kg) were given once every two days, and glucose tolerance test (GTT) and insulin sensitivity test (ITT) were performed respectively during the experiment. During the whole experiment, the normal diet group and the obesity model group were gavaged with an equal volume of 0.5% CMC-Na solution as the experimental control.
[0077] (1) Analysis of body weight and food intake:
[0078] The weight and food intake of mice were recorded from the first day after administration. The weight change data over time are as follows: Figure 3 As shown, ** represents P < 0.01, *** represents P < 0.001, ### Represents P<0.001, NS means not significant. Figure 4 As shown, NS means not significant.
[0079] The data results show that under the condition that the daily food intake of experimental mice is basically the same, the active fraction JST-80% can significantly reduce the body weight of obese mice induced by high-fat diet (HFD). The weight loss effect of the high-dose group (120 mg / kg) is equivalent to that of the positive control group (orlistat). After 40 days of administration, the body weight of mice decreased by 28.1%.
[0080] (2) Oil Red O staining and H&E staining:
[0081] The liver, abdominal fat and kidney were sliced and stained with Oil Red O and H&E. The staining results were as follows: Figure 5 As shown, the accumulation of liver fat can be observed by Oil Red O staining, and the morphology and number of adipocytes can be observed by HE staining.
[0082] The data results show that the active fraction JST-80% can reduce liver fat accumulation in a dose-dependent manner as shown in the Oil Red O staining image, and can be seen from the H&E staining image that the active fraction JST-80% can reduce the volume of adipocytes in adipose tissue, and has little damage to liver and kidney cells, indicating that JST-80% has no hepatotoxicity or renal toxicity.
[0083] (3) Biochemical index detection of serum triglyceride (TG) and cholesterol (TC) content:
[0084] The mice were fasted for 6 h before the end of the animal experiment. Blood was collected by removing the eyeballs and stored in 1.5 mL centrifuge tubes on ice. The blood was centrifuged at 4 °C, 3000 rpm / min for 15 min and the supernatant was collected. Figure 6 As shown, ** represents P < 0.01, NS represents not significant; cholesterol (TC) content is as shown Figure 7 As shown, ** represents P < 0.01, *** represents P < 0.001, and NS means not significant.
[0085] The data results show that the active fraction JST-80% can reduce the blood triglyceride and blood cholesterol concentrations of obese mice, bringing them close to the blood lipid and blood cholesterol levels of normal mice.
[0086] (4) Other blood biochemical indexes:
[0087] As with the above treatment, collect mouse blood in 1.5 mL sodium heparin anticoagulant tubes and store on ice. Centrifuge at 4°C, 3000 rpm / min for 15 minutes, retain the supernatant, and repeat centrifugation once. Use a biochemical automatic analyzer to detect the levels of liver function indicators aspartate aminotransferase (AST) and alanine aminotransferase (ALT), renal function indicators urea nitrogen (UREA) and creatinine (CREA) in the blood to evaluate the in vivo toxicity of the compound. The results are shown in the following table:
[0088]
[0089] The data results show that the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea nitrogen (UREA) and creatinine (CREA) in the blood of the active fraction JST-80% experimental group were not significantly different from those of the normal diet group (Normal diet), so the active fraction JST-80% has no obvious liver and kidney toxicity.
[0090] (5) Glucose tolerance test (OGTT):
[0091] After the mice were treated with the compound for 4 weeks, they were fasted overnight. According to the weight of the mice, the mice were given glucose by gavage at a dose of 2 g / kg, and the blood glucose levels of the mice were tested at 0, 15, 30, 60, 90, and 120 min, respectively, to detect the changes in glucose tolerance of the mice. The test results are as follows: Figure 8 As shown, ** represents P < 0.01, *** represents P < 0.001.
[0092] The data results show that compared with the normal diet group, the fasting blood sugar of the obese model group (HFD diet) is higher, and the blood sugar level increases significantly 15 minutes after oral glucose administration. Over time, the rate of blood sugar reduction in the obese model group (HFD diet) is slower than that in the normal diet group (Normal diet), and the lowest value that blood sugar can reach is higher than that in the normal diet group (Normal diet), indicating that the blood sugar regulation ability of the obese model group (HFD diet) mice has deteriorated and glucose tolerance is impaired. The blood sugar change trend of mice in the JST-80% administration group is similar to that of the normal diet group (Normal diet), indicating that JST-80% can improve glucose tolerance damage caused by a high-fat diet.
[0093] (6) Insulin sensitivity test (ITT):
[0094] After the mice were treated with the compound for 5 weeks, they were fasted for 6 hours. After each mouse was treated with 0.6U insulin intraperitoneally, the blood glucose levels of the mice were tested at 0, 15, 30, 60, 90, and 120 minutes, and the changes in the insulin sensitivity of the mice were tested. The test results are shown in Fig. 9 As shown, ** represents P < 0.01, *** represents P < 0.001.
[0095] The data results show that compared with the normal diet group, the blood sugar of the obese model group (HFD diet) remained at a higher level 15 minutes after intraperitoneal injection of insulin. Over time, the rate of blood sugar reduction in the obese model group (HFD diet) was slower than that in the normal diet group (Normal diet), and the lowest value of blood sugar was higher than that in the normal diet group (Normal diet), indicating that the obese model group (HFD diet) mice had a certain insulin resistance and poor insulin sensitivity. The blood sugar change trend of mice in the JST-80% administration group was similar to that of the normal diet group (Normal diet), indicating that JST-80% can alleviate insulin resistance in obese mice and improve insulin sensitivity.
[0096] The embodiments of the present invention are described in detail above with reference to the accompanying drawings, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations of these embodiments are made without departing from the principles and spirit of the present invention, and still fall within the scope of protection of the present invention.
Claims
1. A lipid-lowering and anti-obesity ginger notoginseng extract, characterized in that: The preparation method thereof comprises the following steps: (1) Crush the raw materials: dry the ginger notoginseng and then crush it; (2) Ethanol extraction: Add 95% ethanol to the raw material for extraction at room temperature for 3 times, with the amount of ethanol added each time being 3-5 times the volume of the raw material, and the extraction time each time being 7 days. Combine the 3 extracts and concentrate under reduced pressure to obtain the ginger notoginseng ethanol extract; (3) Ethyl acetate extraction: The ethanol extract of Panax notoginseng was suspended and dissolved in 5 times the volume of distilled water, and an equal volume of ethyl acetate was added to extract for 3 times. The ethyl acetate extracts were combined and concentrated under reduced pressure to recover the solvent to obtain the ethyl acetate extract of Panax notoginseng; (4) Elution: Using a D101 macroporous resin column, three different concentrations of ethanol-water mixed solvents are used in sequence to elute the ethyl acetate extract of Panax notoginseng in sections, wherein the concentration of the ethanol-water mixed solvent in the first section is greater than or equal to 0:1 and less than or equal to 1:1; the concentration of the ethanol-water mixed solvent in the second section is greater than 1:1 and less than or equal to 4:1; the concentration of the ethanol-water mixed solvent in the third section is greater than 4:1 and less than or equal to 19:1; the corresponding eluates are collected and concentrated under reduced pressure to remove the solvent, thereby obtaining three elution components in sequence: a first section of ethanol macroporous phase, a second section of ethanol macroporous phase and a third section of ethanol macroporous phase; the lipid-lowering and anti-obesity Panax notoginseng extract comprises at least one of the first section of ethanol macroporous phase, the second section of ethanol macroporous phase and the third section of ethanol macroporous phase.
2. The lipid-lowering and anti-obesity ginger Panax notoginseng extract according to claim 1, characterized in that: The specific method of elution in step (4) is as follows: using a D101 macroporous resin column, sequentially using three different concentrations of ethanol-water mixed solvents to segmentally elute the notoginseng ethyl acetate extract, wherein the concentration of the ethanol-water mixed solvent in the first segment is 1:1; the concentration of the ethanol-water mixed solvent in the second segment is equal to 4:1; the concentration of the ethanol-water mixed solvent in the third segment is equal to 19:1; the corresponding eluates are collected respectively, and the solvents are removed by reduced pressure concentration to obtain three elution components in sequence: the first segment ethanol macroporous phase, the second segment ethanol macroporous phase and the third segment ethanol macroporous phase; the lipid-lowering and anti-obesity notoginseng ethyl acetate extract is the second segment ethanol macroporous phase.
3. The lipid-lowering and anti-obesity ginger notoginseng extract according to claim 1, characterized in that: The ginger notoginseng includes at least one of its leaves, stems and roots.
4. A pharmaceutical composition comprising a therapeutically effective amount of the lipid-lowering and anti-obesity Panax notoginseng extract according to any one of claims 1 to 3.
5. Use of the lipid-lowering and anti-obesity Ginger notoginseng extract according to any one of claims 1 to 3 or the pharmaceutical composition according to claim 4 in the preparation of lipid-lowering products.
6. Use of the lipid-lowering and anti-obesity Panax notoginseng extract according to any one of claims 1 to 3 or the pharmaceutical composition according to claim 4 in the preparation of a blood sugar-lowering product.
